Key facts
- It has raised $42.5M; the latest was Early Stage VC ($14.2M) in Dec 2025.
- Notable investors include Legend Capital, Dalton Venture, Ancheng Capital, Cenova Capital, SAFE Pharmaceutical.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for BRC BIOTECHNOLOGY
- ·The full record, as it builds
Funding rounds
No funding rounds for BRC BIOTECHNOLOGY are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BRC BIOTECHNOLOGY
Operator of a biopharmaceuticals testing service platform intend to serve the biotechnology industry. The company is specializes in compliance, quality, and safety testing services, drug discovery, diagnostic equipment, and the biotechnology industry, providing potential treatment to patients.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Website
- brcgroup.cn/
- Ownership
- Privately Held (backing)
BRC BIOTECHNOLOGY doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BRC BIOTECHNOLOGY shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BRC BIOTECHNOLOGY in its N-PORT filings yet. We sweep new filings monthly.